BNP Paribas Financial Markets Grows Position in Astera Labs, Inc. $ALAB

BNP Paribas Financial Markets lifted its holdings in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 577.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,127,340 shares of the company’s stock after purchasing an additional 960,899 shares during the quarter. BNP Paribas Financial Markets owned 0.67% of Astera Labs worth $220,733,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Clearstead Advisors LLC lifted its position in Astera Labs by 13.6% during the third quarter. Clearstead Advisors LLC now owns 636 shares of the company’s stock valued at $125,000 after purchasing an additional 76 shares during the last quarter. Great Valley Advisor Group Inc. increased its holdings in shares of Astera Labs by 2.2% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,119 shares of the company’s stock worth $372,000 after buying an additional 90 shares during the last quarter. Rye Brook Capital LLC raised its position in shares of Astera Labs by 1.1% during the 3rd quarter. Rye Brook Capital LLC now owns 9,200 shares of the company’s stock valued at $1,801,000 after buying an additional 100 shares in the last quarter. Assetmark Inc. raised its position in shares of Astera Labs by 374.1% during the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Finally, SlateStone Wealth LLC lifted its holdings in shares of Astera Labs by 1.3% during the 3rd quarter. SlateStone Wealth LLC now owns 12,744 shares of the company’s stock worth $2,495,000 after acquiring an additional 160 shares during the last quarter. 60.47% of the stock is currently owned by institutional investors.

Insider Transactions at Astera Labs

In related news, CEO Jitendra Mohan sold 94,971 shares of Astera Labs stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total value of $11,758,359.51. Following the transaction, the chief executive officer directly owned 1,452,739 shares of the company’s stock, valued at $179,863,615.59. The trade was a 6.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Philip Mazzara sold 10,000 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $117.47, for a total transaction of $1,174,700.00. Following the sale, the general counsel owned 128,084 shares of the company’s stock, valued at $15,046,027.48. This represents a 7.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 224,292 shares of company stock valued at $27,676,069. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ALAB. Royal Bank Of Canada started coverage on shares of Astera Labs in a research report on Wednesday, January 14th. They issued an “outperform” rating and a $225.00 target price for the company. Citigroup dropped their price target on Astera Labs from $275.00 to $250.00 and set a “buy” rating for the company in a research note on Wednesday, February 11th. BNP Paribas Exane initiated coverage on Astera Labs in a report on Thursday, November 20th. They issued an “outperform” rating for the company. Northland Securities increased their price objective on Astera Labs from $175.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Finally, Loop Capital assumed coverage on Astera Labs in a report on Thursday, March 5th. They set a “buy” rating and a $250.00 price objective on the stock. Fifteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $195.89.

Astera Labs Trading Down 4.8%

Shares of NASDAQ:ALAB opened at $116.48 on Wednesday. The stock has a market capitalization of $19.83 billion, a P/E ratio of 95.48, a price-to-earnings-growth ratio of 2.41 and a beta of 1.74. The stock’s 50-day moving average price is $150.84 and its 200-day moving average price is $169.21. Astera Labs, Inc. has a 12-month low of $47.13 and a 12-month high of $262.90.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The company had revenue of $270.58 million during the quarter, compared to analyst estimates of $249.46 million. During the same quarter in the previous year, the company posted $0.37 EPS. Astera Labs’s revenue for the quarter was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. As a group, research analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.